Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

GSK settles 4 Zantac lawsuits claiming heartburn drug caused cancer

Por: Fox Business Business October 11, 2023

thumbnail

FOX Business host Charles Payne reacts to the 'crisis of trust' in the United States on 'Making Money.' British pharmaceutical company GSK plc settled another lawsuit that claimed its Zantac can cause cancer. The company said Wednesday that it has reached a confidential settlement in the Cantlay/Harper case that was filed in California. The settlement was reached before the trial in that case was slated to begin on November... + full article



Similar News

Drugmaker pays 23andMe $20 million for access to user DNA information

WPTV USA Nation November 03, 2023

thumbnailGlobal drugmaker GSK Plc is buying access to 23andMe's vast collection of consumer  for the price of $20 million.The  company announced Monday it would be extending its five-year collaboration with GSK to allow the London-based pharmaceutical company one year of data... + más

23andMe profile information of some customers surfaces on dark web | Fox Business

Want to help with COVID-19 research? Those who tested positive can share their genetic makeup with DNA testing sites like 23andMe and Ancestry.com. | Chicago Tribune


FDA Panel Backs GSK’s RSV Vaccine for Older People

Time USA Health March 03, 2023

thumbnailGSK Plc’s vaccine for won the support of a key panel of U.S. regulatory advisers for use in people aged 60 and older, as the drugmaker races against Pfizer Inc. to bring to market the first vaccine for RSV. The panel of 12 outside advisers to the Food and Drug Administration... + más

FDA advisors recommend GSK's RSV vaccine for older adults, but flag potential safety risks | CNBC

GSK vaccine for older adults granted FDA priority review | Fox Business


FDA advisors recommend GSK's RSV vaccine for older adults, but flag potential safety risks

CNBC USA Health March 01, 2023

thumbnailwatch nowVIDEO1:5501:55FDA advisory panel votes in favor of adult RSV vaccine from GSK PLCThe Food and Drug Administration's independent panel of advisors on Wednesday recommended RSV vaccine for adults ages 60 and older, though they flagged potential safety issues over... + más

FDA Panel Backs GSK’s RSV Vaccine for Older People | Time

GSK vaccine for older adults granted FDA priority review | Fox Business


Multiple drug makers defeated thousands of lawsuits on Zantac cancer claims

WPTV USA Nation December 07, 2022

thumbnailDrugmakers including Boehringer Ingelheim, GSK Plc, Sanofi SA and Pfizer Inc saw a judge rule in their favor on Tuesday after facing thousands of lawsuits in U.S. federal court over claims the heartburn drug Zantac that they marketed at different times caused cancer. As Reuters... + más

GSK settles 4 Zantac lawsuits claiming heartburn drug caused cancer | Fox Business

GSK 3Q Sales Expected Lower, But Possible Guidance Upgrade on the Horizon -- Earnings Preview | MarketWatch


GSK Raises 2022 Guidance as 3Q Sales Beat Expectations -- Update

MarketWatch USA Business November 02, 2022

thumbnailOperating profit was GBP1.19 billion, down slightly from GBP1.38 billion, due to the fair-value loss on the retained stake in consumer-healthcare business Haleon, which was spun off earlier in the year. Total earnings per share also fell to 18.8 pence from 21.9 pence for the... + más

GSK Raises 2022 Guidance as 3Q Sales Beat Expectations -- Update | MarketWatch

GSK 3Q Sales Expected Lower, But Possible Guidance Upgrade on the Horizon -- Earnings Preview | MarketWatch


GSK vaccine for older adults granted FDA priority review

Fox Business USA Business November 02, 2022

thumbnailCheck out what's clicking on FoxBusiness.com GSK opened 2% higher in U.S. trading Wednesday but closed down 2%. Shares rose after the drugmaker reported financial results that beat Wall Street forecasts and announced the Food and Drug Administration had accepted a biologics... + más

GSK Raises 2022 Guidance as 3Q Sales Beat Expectations -- Update | MarketWatch

GSK Raises 2022 Guidance as 3Q Sales Beat Expectations -- Update | MarketWatch


GSK 3Q Sales Expected Lower, But Possible Guidance Upgrade on the Horizon -- Earnings Preview

MarketWatch USA Business October 31, 2022

thumbnailNET INCOME: Net income at the British pharma major is expected to increase only slightly to GBP1.62 billion from GBP1.17 billion the year prior, according to a company-provided consensus. EPS: Earnings per share are expected at 40.1 pence, from 23.1 pence the previous year. WHAT... + más

Horizon Worlds metaverse app so bad that Meta has to force employees to use it | 9to5Mac

Meta’s VR social network Horizon is too buggy and employees are barely using it | The Verge



About iurex | Privacy Policy | Disclaimer |